News Releases

NEWS RELEASES

  • Webcast
    X Zogenix Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting
    12/03/18 12:00 PM CST
    Click here for webcast

    Zogenix Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting
    12/03/18 12:00 PM CST
Date Title and Summary  
Toggle Summary High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
(GLOBE NEWSWIRE via COMTEX) --Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE,
Toggle Summary Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C. EMERYVILLE, Calif. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system
Toggle Summary New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting
Updated Results of Phase 2 Study of ZX008 in Lennox Gastaut Syndrome to be Presented Data Demonstrating Disease Burden and Negative Impact on Quality of Life of Patients and Families Will Also be Presented EMERYVILLE, Calif. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc.
Toggle Summary Zogenix Announces CFO Transition
Ann D. Rhoads to Depart Company Following Transition Period; Biopharmaceutical Industry Veteran Michael P. Smith Appointed New CFO EMERYVILLE, Calif. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and
Toggle Summary Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
EMERYVILLE, Calif. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today the closing of its previously announced underwritten public offering of 7,705,000
Toggle Summary Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada EMERYVILLE, Calif. , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the
Toggle Summary Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome
EMERYVILLE, Calif. , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that the first child has enrolled in the Phase 3 clinical trial for the Company’s lead
Toggle Summary Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
Issued Patent is First Covering Company’s Treatment of Seizures Associated with Dravet Syndrome Using Fenfluramine as an Adjunctive Therapy EMERYVILLE, Calif. , Jan. 30, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan
Toggle Summary Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
ZX008 Patients More Likely to Achieve Clinically Meaningful Reduction in Seizure Frequency Compared to Those on Placebo Parents/Caregivers and Investigators Rated Patients Treated with ZX008 as Very Much Improved or Much Improved in Overall Condition Compared to Placebo Company to Host Call with
Toggle Summary Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints Zogenix to Host Conference Call Today at 8:30 AM Eastern Time / 5:30 AM
Toggle Summary Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
New Research Expands Understanding of ZX008 Mechanism in Treating Seizures EMERYVILLE, Calif. , May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that
Toggle Summary Zogenix Announces Proposed Public Offering of 4,300,000 Shares of Common Stock
EMERYVILLE, Calif. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions,
Toggle Summary Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
Study 1 Top-Line Data on Track for 3Q 2017 EMERYVILLE, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the last patient has been
Toggle Summary Zogenix Prices Public Offering of Common Stock
EMERYVILLE, Calif. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,700,000 shares of its
Toggle Summary Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome;  Top-Line Results Expected in Third Quarter 2017 IND Accepted by FDA for Phase 3 Clinical Trial of ZX008 in Lennox Gastaut Syndrome Company will host a conference call today at 4:30 p.m. EDT / 1:30 p.m.
Toggle Summary Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox Gastaut Syndrome in 2H 2017 Company will host a conference call today at 4:30 p.m. EST / 1:30 p.m.
Toggle Summary Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan Orphan Drug Designation Granted by FDA for ZX008 in Lennox Gastaut Syndrome; Phase 3 Clinical Trial
Toggle Summary Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndrome Study 1 met primary endpoint of reduction in frequency of convulsive seizures (p
Toggle Summary Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
EMERYVILLE, Calif. , June 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced the U.S. Food & Drug Administration ( FDA ) has granted its investigational
Toggle Summary Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
EMERYVILLE, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the European Commission (EC) has designated ZX008 (fenfluramine) as an
Toggle Summary Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4
EMERYVILLE, Calif. , Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will host an update call on Dravet syndrome and the Company’s investigational
Toggle Summary Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference
EMERYVILLE, Calif. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &
Toggle Summary Zogenix to Participate in the Global Mizuho Investor Conference 2017
EMERYVILLE, Calif. , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.
Toggle Summary Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
EMERYVILLE, Calif. , Feb. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update
Toggle Summary Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
EMERYVILLE, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &
Toggle Summary Zogenix to Present at Stifel 2017 Healthcare Conference
EMERYVILLE, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO of Zogenix , will present a corporate
Toggle Summary Zogenix to Present at the Jefferies 2017 Global Healthcare Conference
EMERYVILLE, Calif. , May 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &
Toggle Summary Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
EMERYVILLE, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31,
Toggle Summary Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9
EMERYVILLE, Calif. , March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year
Toggle Summary Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8
EMERYVILLE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30,
Toggle Summary Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7
EMERYVILLE, Calif. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30,